Skip to main content

Potential antiviral activities of chrysin against hepatitis B virus



Interferon and nucleos(t)ide analogues are current therapeutic treatments for chronic Hepatitis B virus (HBV) infection with the limitations of a functional cure. Chrysin (5, 7-dihydroxyflavone) is a natural flavonoid, known for its antiviral and hepatoprotective activities. However, its anti-HBV activity is unexplored.


In the present study, the anti-hepatitis B activity of chrysin was investigated using the in vitro experimental cell culture model, HepG2 cells. In silico studies were performed where chrysin and lamivudine (used here as a positive control) were docked with high mobility group box 1 protein (HMGB1). For the in vitro studies, wild type HBV genome construct (pHBV 1.3X) was transiently transfected in HepG2. In culture supernatant samples, HBV surface antigen (HBsAg) and Hepatitis B e antigen (HBeAg) were measured by enzyme-linked immunosorbent assay (ELISA). Secreted HBV DNA and intracellular covalently closed circular DNA (cccDNA) were measured by SYBR green real-time PCR. The 3D crystal structure of HMGB1 (1AAB) protein was developed and docked with the chrysin and lamivudine. In silico drug-likeness, Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties of finest ligands were performed by using SwissADME and admetSAR web servers.


Data showed that chrysin significantly decreases HBeAg, HBsAg secretion, supernatant HBV DNA and cccDNA, in a dose dependent manner. The docking studies demonstrated HMGB1 as an important target for chrysin as compared to lamivudine. Chrysin revealed high binding affinity and formed a firm kissing complex with HMGB1 (∆G = − 5.7 kcal/mol), as compared to lamivudine (∆G = − 4.3 kcal/mol), which might be responsible for its antiviral activity.


The outcome of our study establishes chrysin as a new antiviral against HBV infection. However, using chrysin to treat chronic HBV disease needs further endorsement and optimization by in vivo studies in animal models.

Graphical Abstract


Chronic hepatitis B (CHB) disease is a predominant cause of liver cirrhosis and hepatocellular carcinoma (HCC) resulting in significant morbidity and mortality. This contributes to around one million deaths annually [1]. Despite the availability of an effective prophylactic genetically engineered vaccine, chronic hepatitis B continues to be a fundamental health challenge.

Hepatitis B virus (HBV), a member of family “Hepadnaviridae”, has a 3.2 kb partially double stranded, relaxed circular (rc) DNA genome [2]. The virion is made up of envelope protein and is surrounded by icosahedral protein capsid [3]. Upon entry into a hepatocyte, the HBV outer envelope is removed and the nucleocapsid is transported to the nucleus. The rcDNA genome is transformed into covalently closed circular DNA (cccDNA) in the nucleus. CccDNA, also known as minichromosome, is attached with chromatin and represents an essential element in HBV life cycle. CccDNA serves as template for the production of viral transcripts-pregenomic RNA (PgRNA), and PreC/C (3.5 kb), PreS1 (2.4 kb), S (2.1 kb), and X (0.7 kb) messenger ribonucleic acids (mRNAs) [4].

Currently, interferon (IFN-α), its pegylated form (PEG-IFN-α) and nucleoside analogues (NAs) are the anti-HBV candidates of choice and considered as gold standard for the treatment of chronic HBV infection [5, 6]. Though, none of them are effective. These effective candidates' viral specificity is a double-edged sword. Nucleoside analogues function by inhibiting viral HBV polymerase, thus impeding HBV replication. Its long-term administration causes genotype-dependent treatment response, dose dependent side effects, development of drug-resistant mutants, and a strong flare-up of HBV infection, besides the high cost of treatment [7]. Development of resistant HBV strains against most of the licensed antivirals is an emerging clinical problem [8, 9]. There are no available drugs that directly target the covalently closed circular DNA (cccDNA), an important replicative intermediate formed during replication cycle. The existing antivirals are ineffective in completely eradicating the nuclear pool of cccDNA [10]. Approximately 50% of patients on medication do not completely eliminate their viremia during the course of their treatment [11]. Screening of new drugs with effective anti-HBV potential, least or no toxicity, adverse side effects, drug resistance and novel mechanism of action is unquestionably important to combat chronic HBV infection. Consequently, it is important to produce safe, effective and promising anti-HBV candidates that impede viral replication and improve the clinical outcome of HBV affected patients.

The large repertoire of Traditional Chinese medicines (TCMs) possessing abundant natural herbs with antiviral and hepatoprotective properties are frequently used as additional medicines or as substitute to interferon-α and nucleoside analogues because they are less expensive and safer [12]. Traditional Chinese medicines, as a substitutive treatment have heralded a novel scope of therapeutic methods that lead us nearer to the hope to treat chronic HBV disease. In the past decade, ample clinical and experimental studies established various TCMs with tremendous antiviral potential against chronic HBV infection [13]. TCMs, being natural compounds, with diverse structures, offer ample opportunities for testing their anti-HBV potential with unique mechanisms of action [14].

Chrysin, also called 5, 7-dihydroxyflavone, has been used as TCMs for a long time. It is a ubiquitously occurring natural flavonoid found in honey, propolis, and a variety of plant extracts [15]. Antioxidant [16, 17], anti-allergic [18] anti-inflammatory [19], anti-fibrotic [20], anti-cancer [21, 22], and hepatoprotective activities have been demonstrated for chrysin. Chrysin grabbed our attention because of its known antiviral activities [23,24,25], though no published data is available on the anti-HBV activities of chrysin.

Chrysin has been shown to have antiviral activities, although the specific underlying anti-influenza mechanism and its anti-influenza effectiveness in vivo are still mostly unknown. Chrysin's role in blocking cell cycle and apoptosis in several cell lines exposed to two strains of the H1N1 influenza A virus (IAV) and its anti-IAV activity in vivo were examined. They demonstrated that chrysin significantly inhibited IAV replication via a mechanism independent of viral protein interaction and activation of the innate antiviral immune system. Chrysin, notably, can prevent IAV-induced cell cycle arrest in the G0/G1 phase by down-regulating the expression of P53 and P21 and favouring the activation of Cyclin D1/CDK4 and Cyclin E1/CDK2. Chrysin also significantly reduced caspase-9 and caspase-3 activation, altered the balance of Bax/Bcl-xl, and blocked the IAV-triggered mitochondrial apoptotic pathway. Chrysin favoured inhibiting IAV replication in the upper respiratory tract, suggesting that it may be a promising therapeutic drug for preventing the respiratory viruses transmission [26].

Chrysin demonstrated exceptional affinity for SARS-CoV, MERS-CoV, and SARS-CoV 2 Mpro. Furthermore, Chrysin blocked ACE-2 from interacting with the S protein of SARS-CoV-2 [27]. In line with these broad spectrum antiviral activities of chrysin, we reported similar kinds of results in the present study.

In this study we evaluated the effect of chrysin against HBV antigenic secretion in transfected liver cells with pHBV 1.3X wild type recombinant construct containing more than full length genome. We have noticed that chrysin efficiently inhibited secretory proteins in dose-dependent manner. The formation of both HBV covalently closed circular DNA (cccDNA) and  extracellular HBV DNA were reduced by chrysin treatment to a higher extent, representing that chrysin compound targeted replicative intermediate of DNA synthesis. Lack of appropriate animal models makes it herculean to understand the action mechanism of chrysin which is a drawback of present study [28].

In the present study the natural compound chrysin as well as lamivudine standard was docked with High-mobility group box 1 protein (HMGB1). HMGB1 is a nuclear element, signalling biological molecule, important DNA, RNA binding protein, associated with chromatin which serves as a mediator in both acute and chronic inflammation [29]. It is a multifunctional alarmin that plays a predominant role in many biological functions like transcription, DNA repairs and cell development [30]. Furthermore, it has been documented that it boosts the concentration of many proinflammatory cytokines known to play a vital role in triggering liver inflammation in chronic HBV infection, such as tumour necrosis factor (TNF)-α which is linked with chronic HBV disease [31]. HMGB1 a “leaderless cytokine” was found to be an important proinflammatory molecule indicates that many valuable anti-inflammatory drugs could use their action mechanism by impeding its proinflammatory effects and reduce the inflammation rate. Our outcomes of the present in vitro and in silico studies demonstrated novel anti-HBV properties of chrysin.

Materials and methods


Chrysin, a natural compound of cell culture grade was obtained from Sigma-Aldrich Company (St. Louis, MO, USA). Dimethylsulphoxide (Sigma-Aldrich, USA, 100%) was used for dissolving chrysin and 5 mM stock concentration was prepared. Serial dilutions of drug were performed with the Dulbecco’s Modified Eagle's medium (DMEM) cell culture media to get variable concentrations used for in vitro studies. For subsequent experiments, the drug stock was stored in opaque container at 4 °C. The natural compound as well as the other reagents was of molecular biology grade.

Maintenance of cell line

Human hepatoma cell line HepG2 was obtained from National Centre for Cell Sciences (NCCS), Pune, India. Cells were cultured under standard cell culture conditions at 37 °C in a controlled humidified atmosphere with 5% CO2 supply and 100% humidity in CO2 incubator (NuAire NU-5830, USA). Culture was done in 25cm2T- flask (Nunc, Roskilde, Denmark) in Dulbecco’s Modified Eagle's medium (DMEM) enriched with nutrients such as glucose, sodium bicarbonate, sodium pyruvate,4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer supplemented with 10% (v/v) heat inactivated Fetal Bovine Serum (FBS), 1% (v/v) Penicillin–Streptomycin 10,000 U/mL solution (all from Invitrogen, San Diego, CA, USA). The cells were then collected from the flask using 0.25% trypsin (Gibco-BRL, Grand Island, NY, USA) and 1 mmol/L EDTA, and then revived for subsequent investigations. In the drug treatment experiments, cells with passage numbers of 2 to 15 were employed.

Cell toxicity

Prior to the study of antiviral activity against HBV, the cytotoxic effects of the experimental compound were assessed. 3-(4, 5- dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide) (MTT) (Sigma, St. Louis, MO, USA) assay was employed to assess the viability and cytotoxicity, as reported earlier [32]. Briefly, 2 × 104 cells were seeded per well in 96 well plates (CoStar, Corning Inc., NY, USA) and incubated for 6–48 h. The cells were treated with variable concentrations (0, 2.5, 10 and 15 µM) of chrysin and incubated for 72 h. After treatment, MTT solution was prepared by dissolving in PBS (pH 7.4) with final concentration of 0.5 mg/mL. MTT reagent of 100 µL was added in all wells including control. Plate was again kept in culture incubator for 2 to 4 h. Dimethyl sulfoxide (100 µL) was added in each well to dissolve the formazan crystals. After 20 min of incubation, the dissolved dye was quantified spectrophotometrically by taking absorbance at OD 450 nm by an ELSIA plate reader (Bio-Rad, Hercules, CA, USA). The percent cell viability was calculated as per the formula:

$$\% \,{\text{Viability}}\,{ = }\,{{{\text{mean}}\,{\text{OD}}_{{{\text{sample}}}} } \mathord{\left/ {\vphantom {{{\text{mean}}\,{\text{OD}}_{{{\text{sample}}}} } {{\text{mean}}\,{\text{OD}}_{{{\text{control}}}} }}} \right. \kern-0pt} {{\text{mean}}\,{\text{OD}}_{{{\text{control}}}} }} \times 100$$

Chrysin showed its effect on cell viability. IC50 was calculated from the GraphPad Prism version 8.0 software (San Diego, CA. USA). The experiments were performed in triplicates in order to confirm reproducibility. The safer doses derived from this method were employed in subsequent studies.

Transfection with pHBV 1.3X plasmid

The pHBV 1.3X construct harbouring more than full length HBV genome was a kind gift from Dr. Joseph Kock, (Heidelberg, Germany) and Dr. Shiv Kumar Sarin (ILBS, Delhi, India). Briefly, HepG2 cells (2 × 105 cells/well) were seeded into 6-well plate and incubated for 24 h. For transfection, 1 μg of (pHBV 1.3X) wild type construct combined with 3μL of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used per well (Costar, Corning Inc., NY, USA), according to the Lipofectamine 2000 manufacturer instructions.

Drug treatment to transfected HepG2 cells

The non-cytotoxic doses derived from MTT assay were used in subsequent studies. HepG2 cells were treated with safe doses (2.5, 5, 10 and 15 µM) of chrysin and incubated for 72 h. After 72 h post-transfection, culture supernatants were collected for the assessment of HBsAg, HBeAg, and extracellular HBV DNA. The cells were harvested with trypsin digestion, washed three times in phosphate buffered saline (PBS, pH 7.3). The amount of viral DNA in the cellular extract was measured.

Assessment of HBsAg and HBeAg in cell culture supernatant

To measure the HBV secretory proteins from culture supernatants of drug treated cells, the enzyme-linked immunosorbent assay (ELISA) was performed using commercially available ELISA kits-Hepalisa (J Mitra &Co, Delhi, India) and DIA. PRO, MI, (Italy) for HBsAg and HBeAg, respectively. According to the manufacturers’ instructions we performed the analysis of HBsAg and HBeAg in the culture supernatant. In order to confirm the reproducibility of independent experiment, assays were performed in triplicate. The data, presented here as % inhibition of HBsAg and HBeAg, were calculated by the following formula:

$${\text{\% inhibition }} = \, {{\left( {{\text{OD}}_{{{\text{control}}}} {-}{\text{ OD}}_{{{\text{Sample}}}} } \right)} \mathord{\left/ {\vphantom {{\left( {{\text{OD}}_{{{\text{control}}}} {-}{\text{ OD}}_{{{\text{Sample}}}} } \right)} {{\text{OD}}_{{{\text{control}}}} \, \times {\text{ 100\% }}}}} \right. \kern-0pt} {{\text{OD}}_{{{\text{control}}}} \, \times {\text{ 100\% }}}}$$

Assessment of HBV DNA in the supernatant

After 72 h of post-treatment, we observed the effect of compound on the quantity of the extracellular HBV DNA. The culture supernatant was collected by centrifugation at 1200 rpm for 10 min at 4 °C and HBV DNA was isolated and quantified by qPCR (Roche Applied Science, Penzberg, Upper Bavaria, Germany) employing the QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. The oligonucleotide sequence of forward primer was 5′-CCG TCT GTG CCT TCT CAT CTG-3′, the sequence of reverse primer was 5′-AGT CCA AGA GTA CTC TTA TAG AAG ACC TT-3′, and the sequence of Taqman probe was FAM-CCG TGT GCA CTT CGC TTC ACC TCT GC. The PCR program performed included an initial denaturation at 94 °C for 2 min trailed by 40 amplification cycles with each of the two subsequent steps: 95 °C for 5 s and 60 °C for 30 s. Plasmid containing more than the full-length insert of the HBV genome was used to form a standard curve. The standard curve exhibited a satisfying linear range when around 102–107 copies of plasmid DNA were used as template. The inhibitory effects of chrysin on HBV DNA were calculated by the following formula:

$${\text{\% inhibition = }}{{\left( {{\text{Copy number of control}}{-}{\text{ Copy number of sample}}} \right)} \mathord{\left/ {\vphantom {{\left( {{\text{Copy number of control}}{-}{\text{ Copy number of sample}}} \right)} {{\text{Copy number of control }} \times {\text{100\% }}}}} \right. \kern-0pt} {{\text{Copy number of control }} \times {\text{100\% }}}}$$

Purification and quantification of intracellular HBV cccDNA

The effect of chrysin on the level of intracellular cccDNA was observed 72 h post-treatment. For this, cccDNA was isolated from the cell pellet containing 1.0 × 106 cells using mini plasmid extraction Kit (QIAGEN Inc., Chatsworth, CA, USA) following the manufacturer’s instructions. The isolated plasmid was further treated with plasmid safe ATP-dependent DNase (PSAD, Epicentre Technologies, Madison, WI, USA), for 2 h at 37 °C, to eliminate HBV relaxed circular DNA (rcDNA), residual single-stranded viral DNA and cellular chromosomal DNA. This ATP-dependent DNase degrades linear single-stranded and double-stranded DNA, but acts moderately on closed circular double-stranded DNA. The real-time fluorescent quantitative PCR was performed with gene specific primers and Taqman TAMRA fluorescence hybridization probe to detect cccDNA. The sequence of forward primer was 5′-ACT CTT GGA CTC TCA GCA ATG-3′, sequence of reverse primer was 5′-CTT TAT AAG GGT CGA TGT CCA-3′ and sequence of Taqman probe was FAM-CTT TTT CAC CTC TGC CTA ATC ATC TCT TGT TCA- TAMRA. Because of the structural dissimilarities between cccDNA and rcDNA, only cccDNA will be amplified with the designed primers and probe set. PCR conditions were: denaturation for 2 min at 95 °C, followed by 38 cycles of denaturation at 94 °C for 15 s, 58 °C for 30 s, 72 °C for 30 s. The relative quantification of cccDNA was calculated using 2−∆∆Ct method as previously described [33].

Chemical structures and molecular docking studies

In the present study in silico approaches were also used  to trace the active compounds against Hepatitis B virus. It is a convenient drug screening method, where the candidate drugs can be virtually examined at low cost in a short duration. This involves computational simulation of target-ligand interaction and regulates the perfect alignment of binding of one molecule to the second molecule to generate a stable complex. This method, called docking, is used to find the activity of binding of a tiny molecule (in this case, a drug candidate- chrysin, and a positive control lamivudine) to their protein target (in this case HMGB1) by using the scoring functions.

This screening method plays a pivotal role in the functional designing of drug candidates.

Target preparation

HMGB1 (PDB ID: 1AAB) is a signalling protein present in the nucleus. Its crystal structure was downloaded from protein data bank ( We removed the crystallographic water molecules or ligands, in order to produce a free receptor, and to enhance the entropy of the target. The missing polar hydrogen atoms were incorporated, and the energy level of target was minimized while using Swiss_PDB viewer tool. With the help of this server, we speculated the 3D structure of HMGB1 protein. Autogrid 4 module, a bioinformatics tool used to map the protein’s 3D structure, covered all the amino acid residues of the protein. The grid three dimensions X, Y and Z were fixed to be 50, 70 and 58 Å (receptor axis coordinates), and 0.405 Å as grid space size for lamivudine-HMGB1; and 52, 83 and 58 Å (receptor axis coordinates), and 0.435Å as grid space size for chrysin–HMGB1.

Ligand preparation

The molecular structure of lamivudine (positive control) and chrysin was drawn by ChemDraw12 (PerkinElmer Informatics, Waltham, MA, USA) as shown in Fig. 1A and B, respectively. The molecular structure of compounds was converted into 3D form, and geometries were optimized in ChemBio3DUltra12 (PerkinElmer Informatics, Waltham, MA, USA). For docking studies, the tested compound chrysin and positive control lamivudine was saved in PDB format. Molecular docking was performed by using Auto dock 4.2 in order to achieve better insights into the binding mechanism of chrysin and lamivudine with HMGB1. Docking guidelines were followed in this docking simulation. To achieve molecular docking, Lamarckian Genetic Algorithm (LGA) was used to define the best potential structures of the ligands that directly interacted with the target protein. Here the ligand was allowed free to explore and interact with the protein's active site in the best possible or threshold energy configuration. Ideal docked configurations were archived and studied for further interaction between receptor-ligand, employing BOVIA Discovery Studio 4.0 to generate 2D interaction plot [34]. Docking was eventually visualized by Pymol [35]. Lamivudine, a nucleoside analogue approved by FDA for the treatment of chronic hepatitis B virus infection, was also docked with the same protein. In the molecular docking analysis, lamivudine was used as a positive control. For protein–ligand interaction, the binding constant (Kb) was calculated using equation (∆G = − RTlnKb (R = universal gas constant, 1.987 kcal/mol/; T = temperature, 298 K) [36].

Fig. 1
figure 1

A and B represents optimized two-dimensional molecular geometries of anti-HBV compounds lamivudine (nucleoside analogue used as a reference drug in molecular docking analysis only) and chrysin respectively

ADMET examination

The drug-likeness analysis was performed by admetSAR and SwissADME to confirm any cytotoxicity produced by ligands in humans. Several pharmacokinetics properties such as absorption, distribution, metabolism, excretion and toxicity (ADMET) of the tested compound chrysin and the positive control lamivudine were measured with the web tools admetSAR [37] and SwissADME [38]. The physicochemical properties were also studied with the help of these servers.

Statistical analysis

All the results were presented as mean ± standard deviations (SD) of triplicate experiments standardized to control. In the present study, a standard statistical test such as one-way analysis of variance (ANOVA) was done, and data were analyzed to evaluate where precise variances were existing between the samples. Moreover, to define statistical significance Dennett’s t-test was used. GraphPad Prism software version 8.0 was used to calculate the mean and standard deviation, and draw graphs for the results of ELISA, MTT, HBsAg, HBeAg and viral DNA assays. MTT assay was expressed in terms of percentage viability, percentage cytotoxicity and IC50 value, p < 0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).


Effects of chrysin on viability of HepG2 cells

Any potential harmful effect of chrysin on HepG2 cells was investigated using MTT assay prior to starting research on anti-HBV activity. In HepG2 cells, any effect of experimental drug (chrysin) on HBV may get exaggerated by cytotoxicity of the drug itself. Thus, assessing cytotoxicity of chrysin on viability of HepG2 cells is important. For further cell culture assays, the viabilities of HepG2, treated with variable concentrations of chrysin (2.5, 5, 10, 15, 20, 30, 40 µM) were studied after 72 h incubation by MTT assay. Figure 2 shows viability analysis of chrysin which demonstrate that HepG2 viability was almost unaffected up to 15 µM but when the concentration exceeded 15 µM, the cells lost its viability gradually. This also confirms that chrysin did not exhibit any significant effect on cells up to 15 µM, and 20, 30 and 40 µM doses were lethal to cells because these concentrations produced cytotoxicity and therefore were excluded for subsequent experiments. The results also confirmed that test compound maintained viability of cells at concentrations of 2.5–15 µM. Meanwhile, the calculated IC50 of chrysin on HepG2 was 22.5 µM. In a dose dependent fashion, the cells lost viability. Percentage viability of cells at concentrations 2.5, 5, 10, 15, 20, 30 and 40 µM of chrysin was 92.8%, 92.8%, 85%, 83%, 75.2%, 68% and 65.6% respectively. However, 2.5, 5, 10 and 15 µM were the favourable doses for subsequent studies.

Fig. 2
figure 2

Represents cytotoxicity of chrysin measured by MTT assay. Cells seeded in 96-well plate and were incubated overnight. Cells were treated with different concentrations of chrysin. Untreated wells act as a control. In an ELISA reader, the absorbance of the MTT formazan was determined at 450 nm. The percentage of absorbance (OD) of treated cells to untreated cells was measured as % viability. Data presents mean ± standard deviations (SD) of three independent experiments carried out in triplicate. p < 0.05, **p < 0.01, compared with control

Effects of chrysin on HBV virions

To assess the anti-HBV effects of chrysin on the in vitro cell culture system, transformed human hepatoma cell line HepG2 was used that has been transiently transfected with 1.3X pHBV construct. HepG2 was selected because it has been widely used for studying viral life cycle, especially with respect to formation of viral replicative intermediates and cccDNA [39]. Before finding the potential doses that affect HBV replication, it is important to use variable concentrations that are not overtly cytotoxic. Any damage to cell or its functions would interfere virus replications. Therefore, safe doses obtained by MTT assay were used for demonstrating antiviral effects. Effect of chrysin on the expression of viral antigens was studied. HepG2 cells were treated with variable concentrations (2.5, 5, 10 and 15 µM) of chrysin. HBV antigens (HBsAg and HBeAg) secretion was demonstrated in the culture supernatants or cell lysates using ELISA. Treatment of HepG2 cells with chrysin for 72 h leads to a decline in extracellular HBsAg and HBeAg production and the effects were dose-dependent (Figs. 3 and 4) (p < 0.05 or p < 0.01), the inhibitory effect evidently seemed for extracellular HBsAg or HBeAg. The extracellular HBV DNA level was also altered with variable chrysin doses. It was believed that the inhibition of HBsAg and HBeAg might be associated with direct interaction between chrysin and HBV antigen. As understood from Figs. 3 and 4, chrysin could encourage considerable inhibition of HBsAg and HBeAg. The inhibitory potential of chrysin on the secretion of HBeAg was more pronounced than that on the secretion of HBsAg. Chrysin inhibited the secretion of HBsAg and HBeAg by 18%, 25%, 38%, 45% and 25%, 40%, 49%, 58%, respectively (p < 0.05) at a concentration of (2.5, 5, 10 and 15 µM). These results showed that the tested compound could statistically down-regulate secretory proteins levels.

Fig. 3
figure 3

Inhibitory effects of chrysin, in a dose dependent manner, on the levels of HBsAg in HepG2 cells transfected with 1.3X pHBV (replication competent) plasmid. Commercial ELISA kit was used for the detection of HBsAg in the culture supernatants after 72 h incubation. The data are presented as mean ± S.D from three independent experiments

Fig. 4
figure 4

Inhibitory effects of chrysin, in a dose dependent manner, on the levels of HBeAg in HepG2 cells transfected with 1.3X pHBV (replication competent) plasmid. Commercial ELISA kits were used for the detection of HBeAg in the culture supernatants after 72 h incubation. The data represents mean ± S.D from three independent experiments

Effects of chrysin on the replication of extracellular HBV DNA

The quantity of supernatant HBV DNA reveals the HBV replicating potential. Furthermore, to evaluate the efficacy of chrysin against HBV in HepG2 cells, the influence of drug on HBV DNA level in culture supernatant was assessed by safe doses with real-time quantitative PCR. Usually, the levels of secretory proteins (HBeAg, HBsAg) and DNA will be impeded when the HBV replication is inhibited. Treatment of the cells with variable concentrations of chrysin (2.5, 5, 10 and 15 µM) led to a numerically substantial decrease in the level of extracellular HBV DNA as compared with the untreated control. After chrysin treatment for 72 h in a dose dependent fashion, the HBV DNA content in the culture supernatant decreases. The percentage inhibitions of extracellular HBV DNA were 21%, 28.5%, 34.4% and 61% at 2.5, 5, 10 and 15 µM respectively (Fig. 5). However, our mechanistic studies showed that chrysin affects HBV DNA replication, and the percentage inhibition of chrysin on HBsAg and HBeAg reveals that the HBeAg and HBsAg secretion was certainly obstructed in the presence of chrysin. It was observed that chrysin considerably decreased the HBV DNA replication compared to the untreated control (p < 0.01). Our results showed that chrysin had anti-HBV potential in hepatocyte cultures in vitro.

Fig. 5
figure 5

Inhibitory effect of chrysin on the secretion of extracellular HBV DNA in HepG2 cells transfected with 1.3X pHBV in a dose dependent manner. Cells were seeded into 24 well plates and were subjected to the tested compound chrysin and subsequently incubated for 72 h. Samples of HepG2 culture supernatant was collected and the HBV DNA quantified by real-time PCR. Untreated cells acted as control. Each experiment was done in triplicate. The data represents mean ± SD from three independent experiments (ns is non-significant, ***p < 0.001 compared with control)

Inhibitory effects of chrysin on the genesis of intracellular HBV cccDNA pool 

The activity of chrysin on the level of intracellular HBV cccDNA was also studied. After HBV virion entry into hepatocytes, cccDNA is the first replicative intermediate produced, which demonstrates the beginning of intracellular HBV replication and effective development of HBV infection. After cessation of antiviral therapy, cccDNA stubbornness in hepatocytes nuclei is believed to be largely accountable for the recurrence of chronic HBV disease. Thus, the effect on nuclear cccDNA is an essential parameter when assessing an anti-HBV candidate, as an indicator of long-term antiviral response to treatment.

To understand the mechanism of action of chrysin, we tried to examine the effect of chrysin on HBV replication. The level of HBV transcription template (cccDNA) was estimated by using quantitative real-time PCR. We observed that the tested compound chrysin significantly inhibited HBV cccDNA in a dose dependent manner. Enhancing the doses of chrysin caused the inhibition gradually in the formation of intracellular cccDNA as demonstrated in Fig. 6. After treatment with variable concentration of chrysin (2.5, 5, 10 and 15 µM) for 72 h, the intracellular cccDNA reservoir were down regulated by 14.4%, 35.9%, 57.4% and 68.1% respectively as compared with the untreated control. The results suggest that chrysin has a robust inhibitory potential on the genesis of cccDNA pool in a cell culture system. Taken all data together, chrysin might play an unprecedented role in protecting against chronic HBV infection.

Fig. 6
figure 6

Inhibitory effects of chrysin on cccDNA in a dose dependent manner after 72 h of treatment. Cells in untreated wells serve as control. Data are presented as mean ± SD of three independent experiments. p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 compared with control

Molecular docking study

Interaction between lamivudine and HMGB1

Compound lamivudine was docked with HMGB1 protein (PDB ID: 1AAB). The binding energy of lamivudine − 4.3 kcal/mol shows strong affinity with target protein that reflects a binding affinity of 1.0 × 103 per mole (Table 1). Figure 7A provides a cartoon model of the protein as red-green ball and stick pattern. Lamivudine (blue) interacts with various amino acid residues of the protein receptor. Figure 7B provides 2D-plot representation of ligand (lamivudine) interaction with various amino acids of the protein, in which the main residues include GLN20, MET12, SER13, SER14, PHE17, PHE59, ALA16, VAL19, TYR15, and TRP48 via various types of interactions (conventional H-bonding, Pi-Pi T-shaped, Alkyl, Pi-alkyl, van der Waals forces, unfavourable accepter-accepter, unfavourable donor-donor bonds etc.). Table 1 provides residues of the protein that interact with the ligand, various types of interaction, and bond distances between the protein and the drug.

Table 1 Binding sites and various types of interactions occurring between drugs lamivudine (positive control) and chrysin with HMGB1 protein
Fig. 7
figure 7

A Ball and socket cartoon model (blue) of the ligand (lamivudine) positive control interacting with the protein (HMGB1), B 2-D representation of various types of interactions (showed in color codes) of the ligand (lamivudine) in ball and socket model (blue) with specific amino acid residues of the protein

Interaction between chrysin and HMGB1

Compound chrysin was docked with HMGB1 protein. The compound showed Gibbs free energy or binding free energy—5.7 kcal/mol that reflects a binding affinity of 14 × 103 per mole (Table 1). Figure 8A provides a cartoon model of HMGB1 (red-green) as ball and stick pattern, and chrysin (blue) interacting with various amino acid residues of the receptor. Figure 8B provides 2D-plot representation of ligand (chrysin) interaction with amino acids including MET12, ASP 66, MET 62, ALA63, PHE59, GLU60, HIS33, GLN20, ARG23, CYS44,VAL19, PHE17, PHE18, SER14, SER22, PHE 40, TRP48, ALA16 and SER13, of the protein, via various types of interactions (conventional H-bonding, van der Waals forces, Pi-Pi T-shaped, Alkyl, Pi-alkyl, unfavourable acceptor-acceptor, unfavourable donor-donor bonds etc.). Table 1 provides the residues of the protein taking part in interactions with the ligands, shows the types of interactions, and bond distances in between the protein and the drug.

Fig. 8
figure 8

A Ball and socket cartoon model (blue) of the ligand (chrysin) interacting with the protein (HMGB1), B 2-D representation of various types of interactions (showed in color codes) of the ligand (chrysin) in ball and socket model (blue) with specific amino acid residues of the protein

Computational approaches for assessing physicochemical properties, drug-likeness and ADMET properties

We measured the drug potency and toxicity of tested compounds by employing admetSAR and SwissADME online web servers. The results of SwissADME and AdmetSAR web servers illustrates that the molecular weight (MW) of compounds lying within the range of 150-500 g/mol, plays a vital role in drug discovery [40]. Unquestionably, this property can affect several molecular activities like blood brain barrier permeation, absorption and relationship with on-and off-targets [41]. A smaller MW molecule would increase the rate of absorption and therefore most of the drugs are attempted to be maintained at the smallest possible MW. LogPo/w (lipophilicity) is a common term used to evaluate lipophilicity and the partition coefficient between n-octanol and water, and its value must not exceed 5 (between range − 0.7 and 5.0). LogPo/w is responsible for evaluating various ADMET properties including potency. For example, metabolism and solubility are compromised at higher lipophilicity values. The drug permeability is low when the LogPo/w value is low [42]. Topological polar surface area (TPSA) value (range 20-150), is another parameter which suggests the prediction of transport properties or permeability of a candidate molecule in blood brain barrier (BBB), and the gastrointestinal tract. The drug permeability and oral bioavailability are significantly associated with hydrogen bonding (the number of oxygen and nitrogen atoms in a molecule) [40], 43. When passive diffusion makes way into CNS, the TPSA should be less than 80 Å2 [44]. The numbers of hydrogen bond acceptors (HBAs) and hydrogen bonds donors (HBDs) must be within 10 and 5 respectively. HBAs and HBDs are also essential parameters associated with polarity and permeability of candidate drugs [45]. By investigating variations in physicochemical properties of promoted oral drugs over time [46], it was demonstrated that MW and HBAs have considerably augmented, however HBDs and lipophilicity displayed comparatively little fluctuations. These findings propose that the overall sum of HBDs is more important than the count of HBAs [40] for drug designing and formulation, and can be associated with increasing bioavailability factor and membrane permeability [47]. Undoubtedly, for both these parameters, it was revealed that molecules holding higher count of HBAs with little HBDs have promising profile [48]. This is consistent with earlier studies which reveal that HBDs are usually the “foe of drug chemists”. Higher count of HBDs may be the reason of deprived permeability, absorption and bioavailability [49].

In the present study, MW of chrysin is within the acceptable range of 254.24 g/mol, LogP is also within the satisfactory range of 2.27, the TPSA score is 70.67 Å2 which clearly indicates better permeability into tissue. The number of HBA and HBD are 4 and 2 respectively for chrysin. For the positive control lamivudine, MW is 229.26 g/mol, LogP (lipophilicity) is within desirable range 1.04, TPSA is 115.67 Å2, the number of HBA and HBD are 4 and 2 respectively (Table 3). Natural compound chrysin and nucleoside analogue lamivudine were found to follow Lipinski’s rule of 5 (RO5) (Table 2). The RO5 is a mnemonic tool meant for a quick evaluation of molecules to assess their drug-likeness features during drug optimization and discovery. The rule claims that a molecule is expected to show low penetration when a couple of following physicochemical parameters are violated: MW> 500, LogP> 5, HBD> 5, and HBA> 10. The selected compound chrysin and the positive control followed the RO5 with zero violations as mentioned above. Table 2 demonstrates the ADMET profiles of chrysin and lamivudine. Log S implies the solubility of ligands that ideally varies between − 6.5 and 0.5. Chrysin and lamivudine are showing Log S values within the satisfactory range of − 4.19 and − 1.02, respectively. Both CaCo-2 (colorectal carcinoma) and Blood-Brain Barrier (BBB) permeability could be used to evaluate membrane permeability. BBB value represents its well permeation and delivery into the central nervous system (CNS). Blood−brain barrier is the boundary that separates the brain cells from the bloodstream, and serves a crucial role in safeguarding the CNS. It is largely made by the endothelium of brain. It impedes giant molecules by 100% and tiny molecules by 98% from piercing into the CNS, and allows the transport of only water- and lipid-soluble molecules, including selective transport molecules to pass through. The BBB satisfactory values for a suitable drug molecules range between − 3.0 and 1.2 [50]. Lamivudine violated and chrysin followed the BBB value under this ideal range. Both human intestinal absorption (HIA) and gastrointestinal (GI) absorption are positive for both chrysin and lamivudine indicating the absorption of the drugs are good, and are devoid of side effects. Drug metabolism through CYP isoenzymes plays a predominant role in drug interactions which could lead to drug toxicities and diminishing the pharmacological functions. Different cytochrome P450 inhibitors and substrates were studied, and the data are shown in (Table 2). Substrate of P-Glycoprotein (P-gp) serves as a drug eliminating pump which requires energy in the xenobiotic metabolism. Increased P-gp expression is observed in a variety of normal tissues, for example, liver, kidneys (renal tubules), colon, pancreas and adrenal cortex. These reports imply that P-gp may have a secretory physiological function [51]. The P-gp substrate was studied in the present study as shown in (Table 2). In case of toxicity, the tested ligand as well as positive control is labelled as noncarcinogenic and non-toxic. From the Ames mutagenicity test, none of ligands are mutagenic and exhibited a negative response to the Ames test for mutagenicity. The investigation of ADMET profiles of chrysin and lamivudine is important for their clinical use and commercial success as potential CHB drugs. The ADMET results proposed that chrysin can be used as an inhibitor molecule for treatment of chronic HBV (Table 2). Hence, admetSAR and SwissADME servers were important for the determination of molecular, physiochemical and pharmacokinetics properties of drugs.

Table 2 ADMET profile of lamivudine and chrysin estimated from SwissADME and admetSAR


The advent of nucleos(t)ide analogues resistance mutations in the viral polymerase represents a major drawback of the currently available antiviral drugs for treating patients with chronic hepatitis B [52]. Because of this, there is a critical need to develop novel antiviral treatments. Natural flavonoids, alkaloids, saponins, polyphenols, terpenoids and lignans have been documented for potential anti-HBV activities [53, 54], either by means of directly impeding viral replication or regulating host immune‐response [55]. Our study for the first time shows anti-HBV potential of chrysin by in vitro studies. The results are further supported by molecular docking and ADMET analysis. This study is also the first evidence of possible mechanism of action of anti-HBV activity of chrysin. MTT assay (Fig. 2) and subsequent in vitro experiments (Figs. 3, 4, 5, 6) revealed that chrysin had anti-HBV potential at safe doses. Anti-HBV potential of chrysin is correlated with other flavonoids containing broad spectrum of pharmacological properties. Among them one is epigallocatechin-3-gallate (EGCG), a compound derived from green tea. At a concentration of 50 μmol/L, EGCG decreases HBV-host cell entry by > 80% [56]. Further investigations revealed that in a dose and time dependent manner, EGCG had significantly affected HBV life cycle by reducing HBsAg, HBeAg and extracellular HBV DNA in HepG2.2.15 [57, 58]. Wogonin, another flavonoid from Scutellaria radix, efficiently decreases secretion of HBsAg, HBeAg, HBV DNA and viral replication in HepG2.2.15. In humanized HBV-transgenic mice, wogonin substantially decreases HBsAg secretion [59]. In line with these reports, our results show that chrysin decreases HBsAg and HBeAg secretion, extracellular HBV DNA and intracellular cccDNA, in a dose dependent manner, after 72 h post treatment.

Glycyrrhizin has been used for a long time in Japan to treat chronic hepatitis patients. This compound is the first to be reported to target HMGB1 in chronic hepatitis. Our study compound chrysin is very similar to glycyrrhizin, because both are plant derivatives, and exhibit broad-spectrum pharmacological attributes, like antioxidant, anti-cancer, anti-inflammatory and hepatoprotective activities [60,61,62]. In line with these reports, our in silico study, where chrysin and lamivudine (a positive control) are compared for their binding affinities for HMGB1, also demonstrate significant chrysin-HMGB1 binding.

HMGB1 is a well reported cytokine actively involved in increasing the level of proinflammatory molecules such as IL-17 and NF-κB etc., in context of HBV pathogenesis [63]. Several antivirals natural compounds like glycyrrhizin, quercetin and EGCG, that are similar natural plant derivatives as chrysin, are reported to interact directly with HMGB1, and reduce chronic inflammation [64]. Glycyrrhizin is further reported to decrease HBV related chronic liver inflammation via interacting with HMGB1 [60,61,62]. Therefore HMGB1 is an important target for docking studies as has already been mentioned in several reports.

To elucidate and assess the mechanism of action of chrysin as an anti-HBV drug, and the molecular interaction paradigm, we further investigated HMGB1 inhibition by chrysin. This was performed by correlating chrysin with similar natural compounds-quercetin and EGCG. Quercetin is a flavonoid found in fruits and vegetables. In studies involving macrophage cultures, quercetin is reported to inhibit the release of HMGB1 and its cytokine activities, and restricted mitogen-activated protein kinase (MAPK) activation [65].

Another plant derivative, epigallocatechin-3-gallate (EGCG), reduces fatal endotoxemia during systemic inflammation. EGCG, present in Camellia sinensis (component of green tea), protects mice from endotoxemia and fatal sepsis. This is done by reducing HMGB1 formation and release in macrophage cultures, and preventing the clumping of exogenous HMGB1 on macrophage cell surface. The clumping is a key player for HMGB1 induced inflammatory responses [66]. In chronic liver inflammation, HMGB1 plays an important role by enhancing the concentration of proinflammatory cytokines, like IL-17. This cytokine surge encourages infiltration of neutrophils and liver inflammatory response [67]. Up regulation of HMGB1is linked with severity of chronic HBV disease [68]. HMGB1 increases pro-IL-1β levels in macrophages by activating Toll-like receptors (TLR4) signalling, nuclear factor kappa B (NF-κB) and p38 mitogen-activated protein kinase (MAPK) pathways [69]. NF-κB (immune response regulator), p38 and MAPK are associated with inflammation. The receptor for advanced glycation end products (RAGE), a transmembrane protein of immunoglobulin superfamily, that stimulates both innate and adaptive immunity, functions as molecular pattern recognition receptor. The HMGB1 amino acids 150–183 are responsible for RAGE firm binding. The receptor for RAGE interacts with HMGB1 and increases the inflammation rate [70]. It is reported that RAGE activates p38, NF-κB, and MAPK, allowing release of proinflammatory cytokines [71, 72]. Amino acids 89–108 of HMGB1 are responsible for its binding with TLR4 [73]. Therefore, impeding HMGB-1/TLR4 signaling pathway at plasma membrane is effective therapeutic strategy for alleviating chronic HBV infection and reducing liver inflammation. HMGB1 plays predominant role in etiology of liver failure in chronic HBV individuals by impeding immunological activity of regulatory T cells and by down-regulating Foxp3 expression [74].

Docking of lamivudine exhibited that it had significantly bound with HMGB1 active site via generating a rigid lamivudine-HMGB1 complex with an estimated Gibb’s free energy of 4.3 kcal/mol and binding affinity Kb 1.0 × 103 per mole (Table 1). Docking studies (Fig. 7) further proved that lamivudine interacted with HMGB1 by classical and non-classical interactions. Lamivudine interacts with HMGB1 via developing bonds with residues GLN20, MET12, SER13, SER14, PHE17, PHE59, ALA16, VAL19, TYR15, and TRP48.

In order to understand intermolecular interactions and strength of ligand–protein interactions, binding affinities (Kb) of each ligand (chrysin and lamivudine) with the protein (HMGB1) were calculated. Kb is responsible for biological processes, structural biology, and structure–function correlations [75]. Intermolecular weak contacts, such as electrostatic interactions, van der Waals forces, hydrogen bonding, and hydrophobic interactions influence binding affinity. Details of amino acids of the protein that interacted with the drugs (chrysin and lamivudine) are provided in Table 2. The binding sites for each drug were different on the protein and also the different types of interactions took place.

Better understanding of docked protein HMGB1 and inhibitory potential of candidate antiviral molecules could be important breakthrough in exploring treatment options for chronic HBV disease. Strikingly, cellular DNA binding and bending activities are regulated by HMGB1 (serves as chaperone of DNA) [76, 77]. HMGB1 bends DNA and modifies its conformation by unwinding, looping or compacting (Javaherian et al. [77]). Accordingly, we hypothesize that upon HMGB1 binding, HBV DNA may alter its conformation. This change might favor recruitment of regulatory proteins, and inducing HBV replication. In case of viral hepatitis, we hypothesize that chrysin may reduce liver inflammation via HMGB1-TLR4 signaling pathway, in a manner as reported for glycyrrhizin [78]. We postulate that trapping of HMGB1 by chrysin contributes in viral infections by decreasing the level of proinflammatory cytokines induced by HMGB1. We further speculate that chrysin can down regulate expression of inflammatory cytokines and related proteins involved in chronic HBV infection.

When subjected to in silico investigations, chrysin made stable interaction with HMGB1 via MET12, ASP 66, MET 62, ALA63, PHE59, GLU60, HIS33, GLN20, ARG23, CYS44, VAL19, PHE17, PHE18, SER14, SER22, PHE 40, TRP48, ALA16 and SER13 with an approximate binding free energy of − 5.0 kcal/mol and binding affinity (Kb) of 14 × 103 per mole (Table 1) (Fig. 8).

Various research groups demonstrated relationship between physicochemical properties, ADMET profiles and effectiveness of tiny molecules. Drug candidates must be amply permeable and soluble to reach their targets for action. Physicochemical properties calculated for chrysin are MW, logS, LogP, TPSA, HBD, HBA, number of rotatable bonds and molar refractive index (Table 3). As per Lipinski’s rule of five, ligands with less absorption or penetration have hydrogen bond acceptors (HBA) > 10, hydrogen bond donor(HBD) > 5, MW > 500 Da and estimated lipophilicity (LogP) > 5 [79]. It is reported that ligands with rotatable bonds (nrotb) ≤ 10 and total polar surface area (TPSA) of ≤ 140 Å have high bioavailability [80]. In the present study, LogP of chrysin is 2.27, and HBA and HBD are 4 and 2, respectively, which means higher chances of oral bioavailability, absorption and penetration (Table 3).

Table 3 Physicochemical properties of chrysin and lamivudine calculated by SwissADME

Compounds with MW of ≤ 500 Da are rapidly transported, diffused and absorbed as compared to higher MW candidate compounds [81]. In the present study, chrysin and lamivudine fell within the desirable range of MW and therefore easily crosses BBB (Table 3). ADMET parameters of the ligands were demonstrated by using  SwissADME and admetSAR. Parameters such as penetration of BBB, HIA, Caco-2 cell permeability, Ames test and carcinogenicity were measured. Results show that chrysin and lamivudine can be absorbed by the human intestine, penetrates Caco-2 cell (Table 2) and crosses BBB.

Lamivudine was demonstrated to be a potential substrate for P glycoprotein (P-gp), a biomolecule that effluxes drugs and other compounds for subsequent metabolism and clearance [82]. Human microsomal cytochrome P450s (CYP) is responsible for the catalysis of a diverse xenobiotics and pharmaceuticals [83]. Results of Ames test show that chrysin and lamivudine do not display severe toxicity, mutagenicity and carcinogenicity (Table 2).


To conclude, chrysin exhibits the antiviral potential against HBV by lowering HBeAg, HBsAg expressions, extracellular HBV DNA and intracellular cccDNA, in a dose dependent manner. The in vitro investigations were further validated by computational docking analysis (Table 1, Figs. 7A and 8A), which shows that chrysin and lamivudine strongly interact with the active site residues of HMGB1. The interaction of chrysin with HMGB1 might be responsible for its antiviral activities. Analysis of ADMET parameters (Table 2) and physicochemical properties (Table 3) shows that chrysin and lamivudine are suitable for humans without any carcinogenic, mutagenic, and toxic effects. To use chrysin as a treatment of chronic HBV disease, further endorsement and optimization of results by in vivo studies in animal models are needed.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Absorption, distribution, metabolism, excretion and toxicity


Blood–brain barrier


Central nervous system


Covalently closed circular DNA




Enzyme linked immunosorbent assay


Hepatitis B virus


Hepatocellular carcinoma


Hydrogen bond acceptors


Hydrogen bond donors


Human intestinal absorption


High mobility group box 1 protein


3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide


Nucleoside analogues


Rule of five


Standard deviation




  1. Tao Y, et al. Present and future therapies for chronic hepatitis B. Adv Exp Med Biol. 2020;1179:137–86.

    Article  CAS  PubMed  Google Scholar 

  2. Fung J. Prevention of hepatitis B virus recurrence. Hepat Res. 2021;7:33.

    CAS  Google Scholar 

  3. Yan H, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049–e00049.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tu T, Zhang H, Urban S. Hepatitis B virus DNA integration: in vitro models for investigating viral pathogenesis and persistence. Viruses. 2021;13(2):180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol. 2022;11(1):57–72.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lee S, et al. Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes. iScience. 2021;24(1):101969.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bottecchia M, et al. Monitoring the emergence of HBV resistance mutations by HBV-RNA pyrosequencing. Braz J Infect Dis. 2016;20(2):216–7.

    Article  PubMed  Google Scholar 

  9. Yuan C, et al. Reactivation of occult hepatitis b virus infection during long-term entecavir antiviral therapy. Front Microbiol. 2022;13:865124.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–84.

    Article  CAS  PubMed  Google Scholar 

  11. Sun F, Liu Z, Wang B. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study. BMC Cancer. 2021;21(1):1103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Huang K, et al. Traditional Chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021;225:107843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Rahman MA, Ueda K, Honda T. A traditional Chinese medicine, maoto, suppresses hepatitis B virus production. Front Cell Infect Microbiol. 2021;10(894):581345.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chattopadhyay D, et al. Recent advancements for the evaluation of anti-viral activities of natural products. N Biotechnol. 2009;25(5):347–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Siess MH, et al. Flavonoids of honey and propolis: characterization and effects on hepatic drug-metabolizing enzymes and benzo[a]pyrene-DNA binding in rats. J Agric Food Chem. 1996;44(8):2297–301.

    Article  CAS  Google Scholar 

  16. Anand KV, et al. Protective effect of chrysin on carbon tetrachloride (CCl4)-induced tissue injury in male Wistar rats. Toxicol Ind Health. 2011;27(10):923–33.

    Article  CAS  PubMed  Google Scholar 

  17. Pushpavalli G, et al. Effect of chrysin on hepatoprotective and antioxidant status in d-galactosamine-induced hepatitis in rats. Eur J Pharmacol. 2010;631(1–3):36–41.

    Article  CAS  PubMed  Google Scholar 

  18. Bae Y, Lee S, Kim SH. Chrysin suppresses mast cell-mediated allergic inflammation: involvement of calcium, caspase-1 and nuclear factor-κB. Toxicol Appl Pharmacol. 2011;254(1):56–64.

    Article  CAS  PubMed  Google Scholar 

  19. Shin EK, et al. Chrysin, a natural flavone, improves murine inflammatory bowel diseases. Biochem Biophys Res Commun. 2009;381(4):502–7.

    Article  CAS  PubMed  Google Scholar 

  20. Balta C, et al. Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. Chem Biol Interact. 2015;240:94–101.

    Article  CAS  PubMed  Google Scholar 

  21. Khan MS, Devaraj H, Devaraj N. Chrysin abrogates early hepatocarcinogenesis and induces apoptosis in N-nitrosodiethylamine-induced preneoplastic nodules in rats. Toxicol Appl Pharmacol. 2011;251(1):85–94.

    Article  CAS  PubMed  Google Scholar 

  22. Phan T, et al. Antiproliferative effect of chrysin on anaplastic thyroid cancer. J Surg Res. 2011;170(1):84–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wang J, et al. Anti-enterovirus 71 effects of chrysin and its phosphate ester. PLoS ONE. 2014;9(3):e89668.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kim S-R, et al. Antiviral activity of chrysin against influenza virus replication via inhibition of autophagy. Viruses. 2021;13(7):1350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mani R, Natesan V. Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. Phytochemistry. 2018;145:187–96.

    Article  CAS  PubMed  Google Scholar 

  26. Liu Y, et al. Chrysin ameliorates influenza virus infection in the upper airways by repressing virus-induced cell cycle arrest and mitochondria-dependent apoptosis. Front Immunol. 2022;13:872958.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Jha NK, et al. Current understanding of novel coronavirus: molecular pathogenesis, diagnosis, and treatment approaches. Immuno. 2021;1(1):30–66.

    Article  Google Scholar 

  28. Allweiss L, Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol. 2016;64(1 Suppl):S17–31.

    Article  CAS  PubMed  Google Scholar 

  29. Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–51.

    Article  CAS  PubMed  Google Scholar 

  30. Tang D, et al. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab. 2011;13(6):701–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Höhler T, et al. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol. 1998;111(3):579–82.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Ansari S, et al. Quality control, HPTLC analysis, antioxidant and antimicrobial activity of hydroalcoholic extract of roots of qust (Saussurea lappa, C.B Clarke). Drug Metab Pers Ther. 2021;36(2):145–53.

    CAS  Google Scholar 

  33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–8.

    Article  CAS  PubMed  Google Scholar 

  34. Biovia DS. Discovery studio modeling environment, release, vol. 4. San Diego: Dassault Systemes; 2015.

    Google Scholar 

  35. Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rehman MT, Ahmed S, Khan AU. Interaction of meropenem with ‘N’ and ‘B’ isoforms of human serum albumin: a spectroscopic and molecular docking study. J Biomol Struct Dyn. 2016;34(9):1849–64.

    Article  CAS  PubMed  Google Scholar 

  37. Cheng F, et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52(11):3099–105.

    Article  CAS  PubMed  Google Scholar 

  38. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun. 2021;12(1):1591.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Leeson PD. Molecular inflation, attrition and the rule of five. Adv Drug Deliv Rev. 2016;101:22–33.

    Article  CAS  PubMed  Google Scholar 

  41. Gleeson MP, et al. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10(3):197–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov. 2010;5(3):235–48.

    Article  CAS  PubMed  Google Scholar 

  43. Veber DF, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.

    Article  CAS  PubMed  Google Scholar 

  44. Zulfiqar H, et al. Screening of prospective plant compounds as H1R and CL1R inhibitors and its antiallergic efficacy through molecular docking approach. Comput Math Methods Med. 2021;2021:6683407.

    Article  Google Scholar 

  45. Alex A, et al. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. MedChemComm. 2011;2(7):669–74.

    Article  CAS  Google Scholar 

  46. Wenlock MC, et al. A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem. 2003;46(7):1250–6.

    Article  CAS  PubMed  Google Scholar 

  47. Leeson PD, Davis AM. Time-related differences in the physical property profiles of oral drugs. J Med Chem. 2004;47(25):6338–48.

    Article  CAS  PubMed  Google Scholar 

  48. Baell J, et al. Ask the experts: past, present and future of the rule of five. Future Med Chem. 2013;5(7):745–52.

    Article  CAS  PubMed  Google Scholar 

  49. Lipinski CA. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev. 2016;101:34–41.

    Article  CAS  PubMed  Google Scholar 

  50. Yang Y, et al. Transport of active flavonoids, based on cytotoxicity and lipophilicity: an evaluation using the blood–brain barrier cell and Caco-2 cell models. Toxicol In Vitro. 2014;28(3):388–96.

    Article  CAS  PubMed  Google Scholar 

  51. Yamazaki S, Evers R, De Zwart L. Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition. CPT Pharmacomtrics Syst Pharmacol. 2021.

    Article  Google Scholar 

  52. Zhang X, et al. Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection. Sci Rep. 2019;9(1):8078.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Parvez MK, et al. Antiviral natural products against chronic hepatitis B: recent developments. Curr Pharm Des. 2016;22(3):286–93.

    Article  CAS  PubMed  Google Scholar 

  54. Wu Y-H. Naturally derived anti-hepatitis B virus agents and their mechanism of action. World J Gastroenterol. 2016;22(1):188–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Musarra-Pizzo M, et al. Antiviral activity exerted by natural products against human viruses. Viruses. 2021;13(5):828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Huang HC, et al. (−)−Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res. 2014;111:100–11.

    Article  CAS  PubMed  Google Scholar 

  57. Pang JY, et al. Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro. J Zhejiang Univ Sci B. 2014;15(6):533–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Steinmann J, et al. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. 2013;168(5):1059–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Guo Q, et al. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res. 2007;74(1):16–24.

    Article  CAS  PubMed  Google Scholar 

  60. van Rossum TG, et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001;96(8):2432–7.

    Article  PubMed  Google Scholar 

  61. Yamamura Y, et al. The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats. Biopharm Drug Dispos. 1997;18(8):717–25.

    Article  CAS  PubMed  Google Scholar 

  62. Arase Y, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79(8):1494–500.

    Article  CAS  PubMed  Google Scholar 

  63. Inkaya AC, et al. Is serum high-mobility group box 1 (HMGB-1) level correlated with liver fibrosis in chronic hepatitis B? Medicine. 2017;96(36):e7547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Mollica L, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007;14(4):431–41.

    Article  CAS  PubMed  Google Scholar 

  65. Tang D, et al. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol. 2009;41(6):651–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Li W, et al. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS ONE. 2007;2(11):e1153.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Wang X, et al. High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: Interaction of γδ T cells with macrophages. Hepatology. 2013;57(1):373–84.

    Article  CAS  PubMed  Google Scholar 

  68. Liu HB, et al. Serum level of HMGB1 in patients with hepatitis B and its clinical significance. Zhonghua Gan Zang Bing Za Zhi. 2007;15(11):812–5.

    CAS  PubMed  Google Scholar 

  69. He Q, et al. HMGB1 promotes the synthesis of pro-IL-1β and pro-IL-18 by activation of p38 MAPK and NF-κB through receptors for advanced glycation end-products in macrophages. Asian Pac J Cancer Prev. 2012;13(4):1365–70.

    Article  PubMed  Google Scholar 

  70. Kang R, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene. 2014;33(5):567–77.

    Article  CAS  PubMed  Google Scholar 

  71. Yeh CH, et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes. 2001;50(6):1495–504.

    Article  CAS  PubMed  Google Scholar 

  72. Zhu P, et al. Involvement of RAGE, MAPK and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol. 2012;21(2):123–9.

    Article  CAS  PubMed  Google Scholar 

  73. Prantner D, Nallar S, Vogel SN. The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways. FASEB J. 2020;34(12):15659–74.

    Article  CAS  PubMed  Google Scholar 

  74. Wang LW, Chen H, Gong ZJ. High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2010;9(5):499–507.

    CAS  PubMed  Google Scholar 

  75. Ladbury JE, Chowdhry BZ. Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions. Chem Biol. 1996;3(10):791–801.

    Article  CAS  PubMed  Google Scholar 

  76. Chen R, et al. Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med. 2013;19(1):357–66.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Javaherian K, Liu JF, Wang JC. Nonhistone proteins HMG1 and HMG2 change the DNA helical structure. Science. 1978;199(4335):1345–6.

    Article  CAS  PubMed  Google Scholar 

  78. Shi X, et al. Glycyrrhetinic acid alleviates hepatic inflammation injury in viral hepatitis disease via a HMGB1-TLR4 signaling pathway. Int Immunopharmacol. 2020;84:106578–106578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Narkhede RR, et al. Recognition of natural products as potential inhibitors of COVID-19 main protease (Mpro): in-silico evidences. Nat Prod Bioprospect. 2020;10(5):297–306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Zafar F, et al. Physicochemical and pharmacokinetic analysis of anacardic acid derivatives. ACS Omega. 2020;5(11):6021–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Srimai V, et al. Computer-aided design of selective cytochrome P450 inhibitors and docking studies of alkyl resorcinol derivatives. Med Chem Res. 2013;22(11):5314–23.

    Article  CAS  Google Scholar 

  82. Marques SM, et al. Screening of natural compounds as P-glycoprotein inhibitors against multidrug resistance. Biomedicines. 2021;9(4):357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Juvonen RO, et al. Substrate selectivity of coumarin derivatives by human CYP1 enzymes: in vitro enzyme kinetics and in silico modeling. ACS Omega. 2021;6(17):11286–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


Authors are thankful to the host institution Jamia Millia Islamia for providing facility to carry out research work. The authors would also like to extend their sincere thanks to Zahoor Ahmad Parray for his kind assistance during this work. The financial support to SAB from University Grants Commission, New Delhi, is also acknowledged.


SNK sincerely thanks the International Bilateral DST project No. DST/INT/Iran/P-05/2018 for the financial support.

Author information

Authors and Affiliations



SAB and SKH performed all the in vitro experiments. SAB and ZAP carried out in silico studies. SNK and SAB designed the study. SKH, ZAP, SA, AA, SK, FA, MM assisted in the experiments. AI, ZIS and ZM guided in preparation of the manuscript and helped in troubleshooting during experiments. ZIS rechecked the statistical significance of the data, and critically edited the language and scientific content of the manuscript. SNK, SAB and ZIS analysed the data, validated the results with statistical approaches and penned the final draft of manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Syed Naqui Kazim.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that no competing interests exist in publishing this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bhat, S.A., Hasan, S.K., Parray, Z.A. et al. Potential antiviral activities of chrysin against hepatitis B virus. Gut Pathog 15, 11 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Hepatitis B virus
  • Chrysin
  • CccDNA
  • HMGB1
  • In silico